Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New chemo cocktail shows promise for rare childhood brain cancer

NCT ID NCT01270724

Disease control Sponsor: Nationwide Children's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a new combination of chemotherapy drugs (gemcitabine, paclitaxel, and oxaliplatin, or GemPOx) followed by high-dose chemotherapy and a stem cell transplant in 10 patients with recurrent or progressive intracranial germ cell tumors. The goal was to see how well the tumors responded to the initial chemo and whether patients could then proceed to the more intensive transplant phase. The study is completed, but results are not yet widely reported.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Gemcitabine, paclitaxel, and oxaliplatin (GemPOx) followed by high-dose chemotherapy and autologous stem cell rescue
What this could lead to
If successful, this could offer a treatment option for children with recurrent brain germ cell tumors that have not responded to standard therapy.
What could go wrong
This is a very small, early-phase trial with only 10 participants. The combination chemotherapy is intensive and carries significant side effects, and it is not yet known if it will improve long-term survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

10 people

The number who actually took part.

Start date

Aug 2010

Finished

Dec 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ICGCT including pure germinoma and MMGCT. * Patients with histologically proven germinoma and MMGCT, including endodermal sinus tumor (yolk sac tumor), embryonal carcinoma, choriocarcinoma and mixed germ cell tumor will be eligible for the study. * Patients with mature/immature teratoma who have tumor marker elevations are eligible on this study. * Patient with ONLY mature and/or immature teratoma are ineligible in the absence of the tumor marker elevations. Exclusion Criteria: * Patients with ICGCTs who are newly diagnosed are excluded from the study. * Patients with the diagnosis of mature or immature teratoma in the absence of tumor marker elevations are excluded from the study. * Patients who are pregnant or breastfeeding are excluded from the study. * Patients who have received previously a high dose chemotherapy regimen and autologous transplant are excluded from this study. * Patients who have received gemcitabine, oxaliplatin and/or paclitaxel are excluded from this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CNS germ cell tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

central nervous system germ cell tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CNS germ cell tumor

Contacts and locations

Locations

  • Children's Hospital Los Angeles

    Los Angeles, California, 90027, United States

  • Nationwide Children's Hospital

    Columbus, Ohio, 43205, United States

  • New York University Langone Medical Center

    New York, New York, 10016, United States

  • Phoenix Children's Hospital

    Phoenix, Arizona, 85016, United States

  • The Ohio State University Wexner Medical Center_The James Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.